Across TCGA pan-cancer cohorts, ALYREF Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated ALYREF data layer compared with 29 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher ALYREF Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ALYREF expression acts as an unfavorable survival marker.

HNSC, ESCA, and SARC are the cancer types where ALYREF Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	IV	0.122	0.670	.008	9	view →
ESCA	OS	Median	II,III,IV	0.329	0.707	.016	6	view →
SARC	DFS	Median	All	0.180	0.517	.049	3	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: ALYREF tumor-vs-normal RNA expression · all ALYREF data types